SLNOSoleno Therapeutics, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M

Gross Profit

$32M97.9% margin

Operating Income

-$7M-20.0% margin

Net Income

-$5M-14.4% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$332M

Total Liabilities

$92M

Stockholders' Equity

$240M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$0	—
Gross Profit	$32M	-$494,000	+6569.8%
Operating Income	-$7M	-$23M	+71.9%
Net Income	-$5M	-$22M	+78.5%

Revenue Segments

Product

$33M100%

SLNO Q2 2025 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena